A new genetic test called MammaPrint is helping many breast cancer patients. This test determines the risk of cancer ...

The Itovebi-based regimen is approved for the treatment of adults with endocrine-resistant, PIK3CA -mutated, HR-positive, ...

Samuraciclib improved progression-free survival in HR+ advanced breast cancer patients without TP53 mutations or liver ...

Basel: Roche has announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has ...

During a Community Case Forum event, Antoinette R. Tan, MD, MHS, discussed the DESTINY-Breast04 and DESTINY-Breast06 trials ...

Once prostate cancer no longer responds to hormonal therapy, the cancer is called castration-resistant. Find out which ...

Recent phase 2 data support combination treatment with samuraciclib for those with HR+ advanced breast cancer following prior ...

Randee’s cancer had metastasized. When her doctor tested her for the PIK3CA gene mutation, she was able to make informed ...

Roche (OTCQX:RHHBY) (OTCQX:RHHBF) said that an advisory panel of the European Medicines Agency (EMA), endorsed its Itovebi ...

Researchers have discovered a set of alterations in the structure and cellular makeup of breast connective tissue – known as ...

Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children's Oncology Group Between April 2019 and October 2022, 136 and 62 patients were randomly assigned to ...